VRAX
Virax Biolabs Group·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VRAX
Virax Biolabs Group Limited
A provider of viral testing and diagnostic services primarily in the United States and Europe
Healthcare Equipment and Supplies
09/02/2021
07/21/2022
NASDAQ Stock Exchange
19
03-31
Common stock
BioCity Glasgow, Bo’Ness Road Newhouse, Lanarkshire, ML1 5UH, United Kingdom
--
Virax Biolabs Group Limited, a Cayman Islands exempted company incorporated on September 2, 2021, is a global innovative biotechnology group engaged in the sales, distribution and marketing of diagnostic kits, medical technology and personal protective equipment products for the prevention, detection, diagnosis and risk management of viral diseases, with a particular focus on the field of immunology, The product portfolio includes: (i) diagnostic test kits sold through its "ViraxClear" brand; (ii) medical technology and PPE products sold through its "ViraxCare" brand; and (iii) sourcing brands, and also expects to launch a brand "Virax Immune", which aims to provide an immunological analysis platform to assess each person's immune risk profile against major viral diseases worldwide.
Company Financials
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
